121 related articles for article (PubMed ID: 8571286)
1. [Pharmacovigilance seen by a selected group of general practitioners and of residents in the Midi-Pyrénées region].
Pouget-Zago P; Lapeyre-Mestre M; Bagheri H; Montastruc JL
Therapie; 1995; 50(5):459-62. PubMed ID: 8571286
[TBL] [Abstract][Full Text] [Related]
2. [Drug vigilance: opinion survey among residents of a university hospital].
Graille V; Lapeyre-Mestre M; Montastruc JL
Therapie; 1994; 49(5):451-4. PubMed ID: 7855763
[TBL] [Abstract][Full Text] [Related]
3. [Iatrogenic medication: estimation of its prevalence in French public hospitals. Regional Centers of Pharmacovigilance].
Imbs JL; Pouyanne P; Haramburu F; Welsch M; Decker N; Blayac JP; Bégaud B
Therapie; 1999; 54(1):21-7. PubMed ID: 10216418
[TBL] [Abstract][Full Text] [Related]
4. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study.
Durrieu G; Jacquot J; Mège M; Bondon-Guitton E; Rousseau V; Montastruc F; Montastruc JL
Drug Saf; 2016 Dec; 39(12):1189-1195. PubMed ID: 27688025
[TBL] [Abstract][Full Text] [Related]
5. [Adverse effects of locally applied drugs].
Bagheri H; Frelezeau F; Montastruc JL
Therapie; 2000; 55(1):211-9. PubMed ID: 10860026
[TBL] [Abstract][Full Text] [Related]
6. [Follow-up of 'medications and pregnancy' at the Midi-Pyrenees Pharmacovigilance Center'].
Lemoine T; Lacroix I; Lapeyre-Mestre M; Montastruc JL; Damase-Michel C
Therapie; 2001; 56(3):287-93. PubMed ID: 11475810
[TBL] [Abstract][Full Text] [Related]
7. [Adverse drug effect notifications by nurses and comparison with cases reported by physicians].
Sacilotto K; Bagheri H; Lapeyre-Mestre M; Montastruc JL; Montastruc P
Therapie; 1995; 50(5):455-8. PubMed ID: 8571285
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacovigilance of self-medication].
Montastruc JL; Bagheri H; Geraud T; Lapeyre-Mestre M
Therapie; 1997; 52(2):105-10. PubMed ID: 9231503
[TBL] [Abstract][Full Text] [Related]
9. [Organization and results of drug vigilance in France].
Bégaud B; Chaslerie A; Haramburu F
Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
[TBL] [Abstract][Full Text] [Related]
10. [French pharmacovigilance database system: examples of utilisation].
Moore N; Noblet C; Kreft-Jais C; Lagier G; Ollagnier M; Imbs JL
Therapie; 1995; 50(6):557-62. PubMed ID: 8745956
[TBL] [Abstract][Full Text] [Related]
11. [Inter-regional differences in dysthyroidism due to amiodarone: comparison of spontaneous notifications in Aquitaine, Midi-Pyrenees and Languedoc-Roussillon].
Bagheri H; Lapeyre-Mestre M; Levy C; Haramburu F; Hillaire-Buys D; Blayac JP; Montastruc JL
Therapie; 2001; 56(3):301-6. PubMed ID: 11475812
[TBL] [Abstract][Full Text] [Related]
12. Expectations of general practitioners and specialist doctors regarding the feedback received after reporting an adverse drug reaction.
Cornelissen L; van Puijenbroek E; van Grootheest K
Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):76-81. PubMed ID: 17987591
[TBL] [Abstract][Full Text] [Related]
13. Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance.
Henegar C; Bousquet C; Lillo-Le Louët A; Degoulet P; Jaulent MC
Comput Biol Med; 2006; 36(7-8):748-67. PubMed ID: 16185681
[TBL] [Abstract][Full Text] [Related]
14. Documentation and evaluation of adverse drug reactions (ADR)--contribution from a poison information center.
Mey C; Hentschel H; Hippius M; Balogh A
Int J Clin Pharmacol Ther; 2002 Mar; 40(3):102-7. PubMed ID: 11911597
[TBL] [Abstract][Full Text] [Related]
15. [Use of the capture-recapture method to assess the frequency of "serious" adverse drug reactions: experience of Toulouse University Hospital].
Montastruc JL; Lugardon S; Desboeuf K; Fernet P; Lapeyre-Mestre M
Bull Acad Natl Med; 2008 Feb; 192(2):421-30; discussion 430-1. PubMed ID: 18819693
[TBL] [Abstract][Full Text] [Related]
16. A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme.
Bracchi RC; Houghton J; Woods FJ; Thomas S; Smail SA; Routledge PA
Br J Clin Pharmacol; 2005 Aug; 60(2):221-3. PubMed ID: 16042677
[TBL] [Abstract][Full Text] [Related]
17. Drug related hospital admissions in subspecialities of internal medicine.
Hallas J
Dan Med Bull; 1996 Apr; 43(2):141-55. PubMed ID: 8741207
[TBL] [Abstract][Full Text] [Related]
18. Improving medication safety: influence of a patient-specific prescriber feedback program on rate of medication reviews performed by Australian general medical practitioners.
Roughead E; Pratt N; Peck R; Gilbert A
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):797-803. PubMed ID: 17476702
[TBL] [Abstract][Full Text] [Related]
19. [Improving adverse drug reaction reporting by general practitioners through clinical research assistants visits].
Durrieu G; Jacquot J; Baudrin D; Mège M; Rousseau V; Bagheri H; Bondon-Guitton E; Abadie D; Montastruc F; Bismuth M; Oustric S; Montastruc JL
Therapie; 2017 Jun; 72(3):351-355. PubMed ID: 27865436
[TBL] [Abstract][Full Text] [Related]
20. [Satisfaction of a pharmacovigilance declaration support network in general practice].
Driot D; Figuet L; Birebent J; Coste S; Durrieu G; Jacquot J; Bismuth M
Therapie; 2018 Dec; 73(6):483-493. PubMed ID: 29921459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
